{
    "nct_id": "NCT03780517",
    "official_title": "A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)",
    "inclusion_criteria": "Participants are eligible to be included in the study only if all of the following criteria apply:\n\n* Male or female participants must be â‰¥ 18 years, at the time of signing the informed consent\n* Diagnosis of advanced solid tumor with a documented rearranged during transfection (RET) gene altered malignancy as determined locally by a DNA based assay of tumor tissue and/or blood\n* Participants must have no alternative approved therapy.\n* For participants in Part B expansion cohort only: documented local diagnosis of either 1) advanced RET gene fusion non-small cell lung cancer (NSCLC); 2) advanced RET gene mutant medullary thyroid cancer (MTC); or 3) other RET gene altered advanced tumors or NSCLC/MTC with prior specific RET gene targeted therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Negative pregnancy test for females of child bearing potential; must be surgically sterile, postmenopausal, or willing and able to be compliant with a contraceptive regimen\n* Contraceptive use by men or women should be consistent with local regulations.\n* Capable of giving signed informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Participants are excluded from the study if any of the following criteria apply:\n\n* Inability to take oral medications or gastrointestinal (GI) conditions that can interfere with the swallowing or absorption of study medication\n* Uncontrolled or severe concurrent medical condition\n* History of upper GI bleeding, ulceration, or perforation within 12 months prior to the first dose of study drug\n* Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug\n* Participants with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required)\n* Participants who are hepatitis B surface antigen positive or participants who are hepatitis C antibody positive (Participants who have been successfully treated for hepatitis C virus [HCV] are eligible if an undetectable HCV viral load at least 6 months after completion of treatment can be demonstrated.)\n* Any evidence of serious active infections\n* Uncontrolled or severe cardiovascular disease\n* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements\n* Participants with a prior or concurrent malignancy other than the malignancies under study\n* Ongoing cancer directed therapy",
    "miscellaneous_criteria": ""
}